Emerging Therapies Plaque Psoriasis

Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022
March 25, 2022

The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data.

Phase 3 Tapinarof Data Released
December 08, 2021

The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.

Pairing the Right Psoriasis Drug with the Right Patient
November 13, 2021

In a video for Dermatology Times®, Mark Lebwohl, MD, details how to match patients with the right psoriasis treatment for their specific needs.

C-Jun Protein Linked to Psoriasis
June 22, 2021

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application
April 26, 2021

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Biologic Therapy for Psoriasis May Reduce Heart Disease
April 06, 2021

A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.

Study: Depression, Anxiety Reduce Likelihood of Achieving Minimal Disease Activity in PsA Patients
April 06, 2021

A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.

NPF Issues New Guidance Regarding COVID-19 Vaccines
January 22, 2021

New guidance statements related to COVID-19 vaccines and psoriatic disease patients have been published by the National Psoriasis Foundation (NPF) COVID-19 Task Force.

IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral Therapies
January 21, 2021

Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.

Ustekinumab associated with increased cardiovascular risk in some patients
December 22, 2020

A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.